Shots:

• The P-II/III trial evaluate Covaxin on a two-dose schedule administered 28-days apart in 525 children aged 2 to 18yrs. at 6 clinical trial sites across India
• The results showed a robust neutralizing Ab response compared to previous P-III study, ≥93% reduction in severe disease along with favorable safety profile on medRXiv, strong immune response after 2nd dose, increased Abs titers against 3 viral antigens & no serious AEs were reported in any age groups
• Bharat Biotech plans to submit data from the P-III trial to a peer-reviewed scientific publication shortly. Under the recommendation by an independent committee, the data were submitted to the DCGI to support a pediatric indication

Ref: Bharat Biotech | Image: Bharat Biotech